



(11) **EP 3 104 840 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 9/107 ^(2006.01) **A61K 31/415** ^(2006.01)

(86) International application number:
PCT/US2015/015379

(48) Corrigendum issued on:
10.07.2019 Bulletin 2019/28

(87) International publication number:
WO 2015/123272 (20.08.2015 Gazette 2015/33)

(45) Date of publication and mention
of the grant of the patent:
29.05.2019 Bulletin 2019/22

(21) Application number: **15706617.6**

(22) Date of filing: **11.02.2015**

(54) **PARENTERAL COMPOSITIONS OF CELECOXIB**

PARENTERALE ZUSAMMENSETZUNGEN VON CELECOXIB

COMPOSITIONS PARENTÉRALES DE CÉLÉCOXIB

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **11.02.2014 US 201461938338 P**

(43) Date of publication of application:
21.12.2016 Bulletin 2016/51

(73) Proprietor: **Latitude Pharmaceuticals Inc.**
San Diego, CA 92131 (US)

(72) Inventors:
• **OKUMU, Franklin**
Morristown, NJ 07960 (US)
• **CHU, Jan-Jon**
Carlsbad, CA 92010 (US)

• **WEBB, Julie Ann**
San Diego, CA 92103 (US)
• **SABINO, Rafael Anthony**
San Diego, CA 92116 (US)
• **CHEN, Andrew Xian**
San Diego, CA 92121 (US)

(74) Representative: **Bates, Philip Ian**
Reddie & Grose LLP
The White Chapel Building
10 Whitechapel High Street
London E1 8QS (GB)

(56) References cited:
WO-A2-2008/032327 WO-A2-2008/051186
US-A1- 2009 263 486

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
